New Delhi: Zydus Cadila and Taiwan-based pharmaceutical firm TLC have signed a pact to market the drug Liposomal Amphotericin used to treat mucormycosis, commonly known as black fungus, in India. Zydus Cadila announced the signing of the agreement to commercialise AmphoTLC- Amphotericin B Liposome for Injection 50mg- in India in a statement on Wednesday.
As per the agreement, TLC will manufacture and supply AmphoTLC on a non-exclusive basis to Zydus, who will commercialise the drug in India, Zydus said. Sharvil Patel, MD of Cadila Healthcare, said they are making the critical drug available in India immediately as the country is facing an acute shortage. He added that the need of the hour is to tackle the fatal infection with safe and effective therapy. The company added that the Central Drugs Standard Control Organization had approved the drug's application for immediate import per approved usage and indication.
The shares of Cadila Healthcare, the listed entity of Zydus Group, were trading at Rs 626.45 per scrip on the Bombay Stock Exchange, rising 0.64 per cent from the previous close.